Impact autologous bone marrow infusion hematopoietic recovery high-dose cyclophosphamide cisplatin potential tumor contamination inadequacy current purging technique bone marrow patients solid tumors alternative approach high-dose therapy autologous bone marrow ABM infusion levels nonmyeloablative doses cyclophosphamide CVP patients metastatic solid tumors Patients ABM no-ABM NABM infusion CVP impact ABM hematopoietic recovery morbidity mortality patients ABM underwent conventional chemotherapy CVP Seventy-three patients courses similar doses median days neutrophil count ANC /L ABM arm NABM arm levels course course ANCs /L /L levels ABM arm ANC /L comparable arms Incidence infection duration fever similar arms mortality incidence delayed hematopoietic recovery frequent NABM arm significant recovery course arms demonstrable benefit ABM course dose levels ABM recovery ANC /L incidence infections duration fever CVP ABM patients 